Drug Interactions Corner

Back to articles

Beware: Select TKIs interact with pH-altering drugs

KEY POINT

Concurrent use of a proton pump inhibitor (PPI) or H2-receptor antagonist has minimal effects on the efficacy or pharmacokinetics of the tyrosine  kinase inhibitor (TKI) nilotinib (Tasigna—Novartis), according to a retrospective analysis. But results from a recent case report show a significant interaction between dasatinib (Sprycel—Bristol-Myers Squibb) and an H2 blocker.

SOURCES

Yin OQ et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2012;70:345–50. 

Matsuoka A et al. H2-receptor antagonist influences dasatinib pharmackinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;70:351–2. 

Wickersham RM, ed. Drug facts and comparisons. St. Louis, MO: Wolters Kluwer Health; 2012.